Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $215 from $206 and keeps a Neutral rating on the shares following the Q4 report. The firm says the Vyjuvek launch continues to mature while the company’s pipeline serves as an “upside lever.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech’s Strong Growth Prospects and Pipeline Catalysts Justify Buy Rating
- Krystal Biotech Reports Robust 2024 Financial Growth
- Buy Recommendation for Krystal Biotech Based on Strong Performance and Strategic Pricing
- Krystal Biotech price target raised to $218 from $212 at Chardan
- Krystal Biotech: Strong Financials and Strategic Growth Support Buy Rating